Omnicell (NASDAQ:OMCL) Updates FY 2025 Earnings Guidance

Omnicell (NASDAQ:OMCL) updated its FY 2025 earnings guidance on Thursday. The company provided earnings per share guidance of 1.650-1.850 for the period, compared to the consensus earnings per share estimate of 1.790. The company issued revenue guidance of $1.1 billion-$1.2 billion, compared to the consensus revenue estimate of $1.2 billion. Omnicell also updated its Q1 2025 guidance to 0.150-0.250 EPS.

Omnicell Price Performance

Shares of NASDAQ OMCL opened at $40.16 on Friday. The firm has a 50-day moving average of $44.21 and a two-hundred day moving average of $43.29. The company has a market capitalization of $1.86 billion, a price-to-earnings ratio of 148.75, a PEG ratio of 26.98 and a beta of 0.78. The company has a current ratio of 1.37, a quick ratio of 0.95 and a debt-to-equity ratio of 0.13. Omnicell has a twelve month low of $25.12 and a twelve month high of $55.74.

Omnicell (NASDAQ:OMCL) last issued its earnings results on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. As a group, analysts expect that Omnicell will post 1.04 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of equities analysts recently weighed in on the company. Bank of America decreased their price target on Omnicell from $54.00 to $46.00 and set a “neutral” rating for the company in a research report on Monday, January 6th. Benchmark reiterated a “buy” rating and issued a $62.00 target price on shares of Omnicell in a report on Tuesday. Wells Fargo & Company cut their price target on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a report on Monday, January 13th. Craig Hallum raised their price objective on shares of Omnicell from $45.00 to $64.00 and gave the stock a “buy” rating in a research note on Thursday, October 31st. Finally, JPMorgan Chase & Co. boosted their target price on shares of Omnicell from $37.00 to $44.00 and gave the company a “neutral” rating in a research note on Thursday, November 21st. Five investment analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat, the company presently has an average rating of “Hold” and an average price target of $52.33.

Insider Buying and Selling

In related news, Director Mark W. Parrish sold 12,000 shares of the company’s stock in a transaction dated Tuesday, December 10th. The shares were sold at an average price of $47.30, for a total transaction of $567,600.00. Following the transaction, the director now owns 58,427 shares in the company, valued at $2,763,597.10. This represents a 17.04 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 2.64% of the stock is currently owned by corporate insiders.

About Omnicell

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.